Johnson & Johnson Reports 2013 Second-Quarter Results:

Sales of $17.9 Billion increased 8.5% Versus 2012 Second Quarter;

Second-Quarter EPS was $1.33

Excluding Special Items, 2013 Second-Quarter EPS of $1.48 Increased 13.8%*

Jul 16, 2013, 07:47 ET from Johnson & Johnson

 

 

NEW BRUNSWICK, N.J., July 16, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.9 billion for the second quarter of 2013, an increase of 8.5% as compared to the second quarter of 2012.  Operational results increased 10.0% and the negative impact of currency was 1.5%.  Domestic sales increased 8.0%.  International sales increased 9.0%, reflecting operational growth of 11.8% and a negative currency impact of 2.8%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 5.6%.

Net earnings and diluted earnings per share for the second quarter of 2013 were $3.8 billion and $1.33, respectively.  The second quarter results included the gain on the sale of the equity interest owned in Elan Corporation, plc, as previously disclosed. Second quarter 2013 net earnings included after-tax special items of approximately $0.5 billion, related to litigation expenses, integration and transaction costs associated with the acquisition of Synthes, Inc, and program costs associated with the DePuy ASRTM Hip. Second quarter 2012 net earnings included after-tax special items of approximately $2.2 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.3 billion and diluted earnings per share were $1.48, representing increases of 17.7% and 13.8%, respectively, as compared to the same period in 2012.*  

"Our strong second-quarter results reflect the progress we've made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business," said Alex Gorsky, Chairman and Chief Executive Officer.  "Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth."

The Company increased its earnings guidance for full-year 2013 to $5.40 - $5.47 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 1.1% versus the prior year consisting of an operational increase of 1.7% and a negative impact from currency of 0.6%.  Domestic sales increased 1.0%.  International sales increased 1.1%, which reflected an operational increase of 2.0% and a negative currency impact of 0.9%.

Positive contributors to operational results were upper respiratory over-the-counter medicines; TYLENOL® and MOTRIN® analgesics; international sales of LISTERINE® mouthwash; baby care products and women's sanitary protection products.

Worldwide Pharmaceutical sales of $7.0 billion for the second quarter represented an increase of 11.7% versus the prior year with operational growth of 12.9% and a negative impact from currency of 1.2%.  Domestic sales increased 9.1%.  International sales increased 14.1% which reflected an operational increase of 16.5% and a negative currency impact of 2.4%. 

Primary contributors to operational sales growth were REMICADE® (infliximab) and SIMPONI® (golimumab),  biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; VELCADE® (bortezomib), a treatment for multiple myeloma;  PREZISTA® (darunavir), a treatment for HIV; and sales of recently launched products.

The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; and INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus.

During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

Additionally, the FDA granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD. Daratumumab is an investigational human CD38 monoclonal antibody licensed from Genmab A/S.

In addition, a New Drug Application was submitted to the FDA under Breakthrough Therapy Designation for the use of ibrutinib in previously treated patients with chronic lymphocytic leukemia /small lymphocytic lymphoma, and for use in previously treated patients with mantle cell lymphoma.

Also during the quarter, a Marketing Authorization Application was submitted to the European Medicines Agency seeking approval for simeprevir (TMC435). Simeprevir is a new generation NS3/4A protease inhibitor, administered as one 150mg capsule once daily in combination with peginterferon alfa and ribavirin, indicated for the treatment of genotype 1 or genotype 4 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis), with or without HIV-1 co-infection, who are treatment naive or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin.

The Committee for Medical Products for Human Use of The European Medicines Agency granted a positive opinion on two variations relating to the use of VELCADE® (bortezomib). The first recommendation was for the use of VELCADE® as retreatment in adult patients who have previously responded to treatment with the same medicine. The second recommendation was as induction therapy in combination with dexamethasone or dexamethasone and thalidomide for adult patients with previously untreated multiple myeloma that are eligible for high-dose chemotherapy with haematological stem cell transplantation. In addition, the European Commission approved a new twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, in combination with pegylated-interferon and ribavirin for naive and previous treatment experienced patients.

A definitive agreement was signed in June to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program.  Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second quarter represented an increase of 9.6% versus the prior year consisting of an operational increase of 12.0% and a negative currency impact of 2.4%.  Domestic sales increased 9.8%.  International sales increased 9.4%, which reflected an operational increase of 13.7% and a negative currency impact of 4.3%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 0.5%.

Primary contributors to operational growth were sales from the acquisition of Synthes, Inc., in the Orthopaedics business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; Vision Care's 1-Day ACUVUE® TRUEYE and 1-Day ACUVUE® MOIST® disposable contact lenses; and biosurgical and international sales of energy products in the Specialty Surgery business. 

During the quarter, the FDA granted Premarket Approval for the SEDASYS® System, the first computer-assisted personalized sedation system for healthy patients undergoing sedation during routine colonoscopy and esophagogastroduodenoscopy procedures.

About Johnson & Johnson    Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.jnj.com.

NOTE TO INVESTORS 

(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

                      Percent                       Change

                        Percent                         Change

2013

2012

Total

Operations

Currency

2013

2012

Total

Operations

Currency

Sales to customers by

segment of business

Consumer

    U.S.

$  1,326

1,313

1.0

%

1.0

-

$  2,674

2,629

1.7

%

1.7

-

    International

2,332

2,306

1.1

2.0

(0.9)

4,659

4,585

1.6

2.9

(1.3)

3,658

3,619

1.1

1.7

(0.6)

7,333

7,214

1.6

2.4

(0.8)

Pharmaceutical

    U.S.

3,377

3,094

9.1

9.1

-

6,848

6,120

11.9

11.9

-

    International

3,648

3,197

14.1

16.5

(2.4)

6,945

6,304

10.2

12.4

(2.2)

7,025

6,291

11.7

12.9

(1.2)

13,793

12,424

11.0

12.1

(1.1)

Med Devices & Diagnostics

    U.S.

3,243

2,953

9.8

9.8

-

6,449

5,830

10.6

10.6

-

    International

3,951

3,612

9.4

13.7

(4.3)

7,807

7,146

9.2

12.9

(3.7)

7,194

6,565

9.6

12.0

(2.4)

14,256

12,976

9.9

12.0

(2.1)

U.S.

7,946

7,360

8.0

8.0

-

15,971

14,579

9.5

9.5

-

International

9,931

9,115

9.0

11.8

(2.8)

19,411

18,035

7.6

10.2

(2.6)

Worldwide

$17,877

16,475

8.5

%

10.0

(1.5)

$35,382

32,614

8.5

%

9.9

(1.4)

 

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2013

2012

Total

Operations

Currency

2013

2012

Total

Operations

Currency

Sales to customers by

geographic area

U.S.

$  7,946

7,360

8.0

%

8.0

-

$15,971

14,579

9.5

%

9.5

-

Europe

4,672

4,165

12.2

11.4

0.8

9,153

8,359

9.5

8.8

0.7

Western Hemisphere excluding U.S.

1,905

1,728

10.2

14.0

(3.8)

3,688

3,442

7.1

11.5

(4.4)

Asia-Pacific, Africa

3,354

3,222

4.1

11.0

(6.9)

6,570

6,234

5.4

11.4

(6.0)

International

9,931

9,115

9.0

11.8

(2.8)

19,411

18,035

7.6

10.2

(2.6)

Worldwide

$17,877

$16,475

8.5

%

10.0

(1.5)

$35,382

$32,614

8.5

%

9.9

(1.4)

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

2013

2012

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$     17,877

100.0

$     16,475

100.0

8.5

Cost of products sold

5,489

30.7

5,143

31.2

6.7

Selling, marketing and administrative expenses

5,376

30.1

4,965

30.1

8.3

Research and development expense

1,946

10.9

1,766

10.7

10.2

In-process research and development

-

-

429

2.6

Interest (income) expense, net

101

0.6

129

0.8

Other (income) expense, net

172

0.9

2,008

12.2

Earnings before provision for taxes on income

4,793

26.8

2,035

12.4

135.5

Provision for taxes on income

960

5.4

627

3.9

53.1

Net earnings

$       3,833

21.4

$       1,408

8.5

172.2

Net earnings per share (Diluted)

$         1.33

$         0.50

166.0

Average shares outstanding (Diluted)

2,893.0

2,798.2

Effective tax rate

20.0

%

30.8

%

Adjusted earnings before provision for taxes and net earnings (1)

  Earnings before provision for taxes on income

$       5,359

30.0

$       4,646

28.2

15.3

  Net earnings

$       4,289

24.0

$       3,644

22.1

17.7

  Net earnings per share (Diluted)

$         1.48

$         1.30

13.8

  Effective tax rate

20.0

%

21.6

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings 

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

2013

2012

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$     35,382

100.0

$     32,614

100.0

8.5

Cost of products sold

11,043

31.2

10,058

30.8

9.8

Selling, marketing and administrative expenses

10,599

30.0

9,980

30.6

6.2

Research and development expense

3,730

10.5

3,411

10.5

9.4

In-process research and development

64

0.2

429

1.3

Interest (income) expense, net

205

0.6

259

0.8

Other (income) expense, net

687

1.9

1,397

4.3

Earnings before provision for taxes on income

9,054

25.6

7,080

21.7

27.9

Provision for taxes on income

1,724

4.9

1,762

5.4

(2.2)

Net earnings

$       7,330

20.7

$       5,318

16.3

37.8

Net earnings per share (Diluted)

$         2.55

$         1.91

33.5

Average shares outstanding (Diluted)

2,878.8

2,792.4

Effective tax rate

19.0

%

24.9

%

Adjusted earnings before provision for taxes and net earnings (1)

  Earnings before provision for taxes on income

$     10,429

29.5

$       9,574

29.4

8.9

  Net earnings

$       8,396

23.7

$       7,448

22.8

12.7

  Net earnings per share (Diluted)

$         2.92

$         2.67

9.4

  Effective tax rate

19.5

%

22.2

%

(1) See Reconciliation of Non-GAAP Financial Measures.

 

Johnson & Johnson and Subsidiaries

Reconciliation of Non-GAAP Financial Measures

Second Quarter

% Incr. /

Six Months YTD

% Incr. /

(Dollars in Millions Except Per Share Data)

2013

2012

(Decr.)

2013

2012

(Decr.)

Earnings before provision for taxes on income - as reported

$   4,793

2,035

135.5

%

$   9,054

$   7,080

27.9

%

Intangible asset write-downs

-

939

-

939

Litigation expenses

375

669

904

669

Synthes integration/transaction costs and currency related

122

574

380

457

In-process research and development

-

429

64

429

DePuy ASR™Hip program

69

-

82

-

Other

-

-

(55)

-

Earnings before provision for taxes on income - as adjusted

$   5,359

4,646

15.3

%

$ 10,429

9,574

8.9

%

Net Earnings - as reported

$   3,833

1,408

172.2

%

$   7,330

5,318

37.8

%

Intangible asset write-downs

-

717

-

717

Litigation expenses

308

611

699

611

Synthes integration/transaction costs and currency related

87

564

270

458

In-process research and development

-

344

42

344

DePuy ASR™Hip program

61

-

91

-

Other

-

-

(36)

-

Net Earnings - as adjusted 

$   4,289

3,644

17.7

%

$   8,396

7,448

12.7

%

Diluted Net Earnings per share - as reported

$     1.33

0.50

166.0

%

$     2.55

1.91

33.5

%

Intangible asset write-downs

-

0.26

-

0.26

Litigation expenses

0.10

0.22

0.24

0.22

Synthes integration/transaction costs and currency related

0.03

0.20

0.09

0.16

In-process research and development

-

0.12

0.02

0.12

DePuy ASR™Hip program

0.02

-

0.03

-

Other

-

-

(0.01)

-

Diluted Net Earnings per share - as adjusted 

$     1.48

1.30

13.8

%

$     2.92

2.67

9.4

%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes 

on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) (4)

BABY CARE

US

$          106

106

0.0%

0.0%

-

$          209

205

2.0%

2.0%

-

Intl

480

472

1.7%

3.8%

-2.1%

941

913

3.1%

5.7%

-2.6%

WW

586

578

1.4%

3.1%

-1.7%

1,150

1,118

2.9%

5.0%

-2.1%

ORAL CARE

US

149

159

-6.3%

-6.3%

-

307

314

-2.2%

-2.2%

-

Intl

257

249

3.2%

4.3%

-1.1%

502

481

4.4%

5.8%

-1.4%

WW

406

408

-0.5%

0.2%

-0.7%

809

795

1.8%

2.6%

-0.8%

OTC (3)

US

290

247

17.4%

17.4%

-

644

538

19.7%

19.7%

-

Intl

641

636

0.8%

0.9%

-0.1%

1,330

1,296

2.6%

3.0%

-0.4%

WW

931

883

5.4%

5.4%

0.0%

1,974

1,834

7.6%

7.9%

-0.3%

SKIN CARE

US

463

471

-1.7%

-1.7%

-

916

924

-0.9%

-0.9%

-

Intl

445

442

0.7%

1.0%

-0.3%

894

896

-0.2%

0.3%

-0.5%

WW

908

913

-0.5%

-0.4%

-0.1%

1,810

1,820

-0.5%

-0.3%

-0.2%

WOMEN'S HEALTH

US

84

80

5.0%

5.0%

-

165

173

-4.6%

-4.6%

-

Intl

327

322

1.6%

3.4%

-1.8%

647

638

1.4%

4.1%

-2.7%

WW

411

402

2.2%

3.6%

-1.4%

812

811

0.1%

2.2%

-2.1%

WOUND CARE/OTHER (3)

US

234

250

-6.4%

-6.4%

-

433

475

-8.8%

-8.8%

-

Intl

182

185

-1.6%

-1.4%

-0.2%

345

361

-4.4%

-4.0%

-0.4%

WW

416

435

-4.4%

-4.3%

-0.1%

778

836

-6.9%

-6.7%

-0.2%

TOTAL CONSUMER

US

1,326

1,313

1.0%

1.0%

-

2,674

2,629

1.7%

1.7%

-

Intl

2,332

2,306

1.1%

2.0%

-0.9%

4,659

4,585

1.6%

2.9%

-1.3%

WW

$       3,658

3,619

1.1%

1.7%

-0.6%

$       7,333

7,214

1.6%

2.4%

-0.8%

See footnotes at end of schedule

Supplemental Sales Information

2012

2013

Q1

Q2

Q3

Q4

FY

Q1

OTC

US

291

247

263

273

1,074

354

Intl

660

636

653

743

2,692

689

WW

951

883

916

1,016

3,766

1,043

WOUND CARE/OTHER

US

225

250

214

195

884

199

Intl

176

185

163

152

676

163

WW

401

435

377

347

1,560

362

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)

IMMUNOLOGY

US

$       1,578

1,471

7.3%

7.3%

-

$       3,217

2,924

10.0%

10.0%

-

Intl

663

448

48.0%

51.5%

-3.5%

1,228

890

38.0%

40.9%

-2.9%

WW

2,241

1,919

16.8%

17.6%

-0.8%

4,445

3,814

16.5%

17.2%

-0.7%

REMICADE

US 

926

890

4.0%

4.0%

-

1,896

1,772

7.0%

7.0%

-

US Exports (5)

332

366

-9.3%

-9.3%

-

681

744

-8.5%

-8.5%

-

Intl

414

267

55.1%

58.2%

-3.1%

695

28

31.6%

34.0%

-2.4%

WW

1,672

1,523

9.8%

10.3%

-0.5%

3,272

3,044

7.5%

7.9%

-0.4%

SIMPONI

US

87

63

38.1%

38.1%

-

181

127

42.5%

42.5%

-

Intl

88

62

41.9%

48.3%

-6.4%

231

114

*

*

-4.5%

WW

175

125

40.0%

43.2%

-3.2%

412

241

71.0%

73.5%

-2.5%

STELARA

US

233

152

53.3%

53.3%

-

459

281

63.3%

63.3%

-

Intl

138

96

43.8%

45.4%

-1.6%

258

188

37.2%

38.4%

-1.2%

WW

371

248

49.6%

50.2%

-0.6%

717

469

52.9%

53.4%

-0.5%

OTHER IMMUNOLOGY

US

-

-

-

-

-

-

-

-

-

-

Intl

23

23

0.0%

1.1%

-1.1%

44

60

-26.7%

-26.1%

-0.6%

WW

23

23

0.0%

1.1%

-1.1%

44

60

-26.7%

-26.1%

-0.6%

INFECTIOUS DISEASES

US

259

237

9.3%

9.3%

-

497

479

3.8%

3.8%

-

Intl

711

551

29.0%

30.2%

-1.2%

1,288

1,064

21.1%

22.2%

-1.1%

WW

970

788

23.1%

23.9%

-0.8%

1,785

1,543

15.7%

16.5%

-0.8%

INCIVO

US

-

-

-

-

-

-

-

-

-

-

Intl

172

102

68.6%

71.8%

-3.2%

334

234

42.7%

45.4%

-2.7%

WW

172

102

68.6%

71.8%

-3.2%

334

234

42.7%

45.4%

-2.7%

INTELENCE

US

44

42

4.8%

4.8%

-

91

85

7.1%

7.1%

-

Intl

59

49

20.4%

21.0%

-0.6%

101

86

17.4%

18.0%

-0.6%

WW

103

91

13.2%

13.5%

-0.3%

192

171

12.3%

12.6%

-0.3%

PREZISTA

US

196

166

18.1%

18.1%

-

363

326

11.3%

11.3%

-

Intl

239

207

15.5%

16.0%

-0.5%

439

371

18.3%

18.7%

-0.4%

WW

435

373

16.6%

16.9%

-0.3%

802

697

15.1%

15.3%

-0.2%

OTHER INFECTIOUS DISEASES

US

19

29

-34.5%

-34.5%

-

43

68

-36.8%

-36.8%

-

Intl

241

193

24.9%

25.8%

-0.9%

414

373

11.0%

11.9%

-0.9%

WW

260

222

17.1%

17.9%

-0.8%

457

441

3.6%

4.3%

-0.7%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

NEUROSCIENCE

US

626

658

-4.9%

-4.9%

-

1,372

1,332

3.0%

3.0%

-

Intl

1,054

1,056

-0.2%

3.8%

-4.0%

2,052

2,029

1.1%

4.6%

-3.5%

WW

1,680

1,714

-2.0%

0.4%

-2.4%

3,424

3,361

1.9%

4.0%

-2.1%

CONCERTA/METHYLPHENIDATE

US

85

146

-41.8%

-41.8%

-

224

343

-34.7%

-34.7%

-

Intl

130

122

6.6%

8.9%

-2.3%

247

233

6.0%

7.9%

-1.9%

WW

215

268

-19.8%

-18.7%

-1.1%

471

576

-18.2%

-17.4%

-0.8%

INVEGA

US

76

76

0.0%

0.0%

-

147

145

1.4%

1.4%

-

Intl

74

66

12.1%

18.3%

-6.2%

135

118

14.4%

19.9%

-5.5%

WW

150

142

5.6%

8.4%

-2.8%

282

263

7.2%

9.7%

-2.5%

INVEGA SUSTENNA/ XEPLION

US

158

120

31.7%

31.7%

-

322

220

46.4%

46.4%

-

Intl

132

75

76.0%

75.0%

1.0%

252

136

85.3%

84.4%

0.9%

WW

290

195

48.7%

48.3%

0.4%

574

356

61.2%

60.9%

0.3%

RISPERDAL CONSTA

US

107

110

-2.7%

-2.7%

-

213

223

-4.5%

-4.5%

-

Intl

229

245

-6.5%

-3.7%

-2.8%

458

493

-7.1%

-4.9%

-2.2%

WW

336

355

-5.4%

-3.5%

-1.9%

671

716

-6.3%

-4.8%

-1.5%

OTHER NEUROSCIENCE

US

200

206

-2.9%

-2.9%

-

466

401

16.2%

16.2%

-

Intl

489

548

-10.8%

-5.5%

-5.3%

960

1,049

-8.5%

-3.7%

-4.8%

WW

689

754

-8.6%

-4.8%

-3.8%

1,426

1,450

-1.7%

1.8%

-3.5%

ONCOLOGY

US

206

119

73.1%

73.1%

-

405

226

79.2%

79.2%

-

Intl

679

467

45.4%

48.1%

-2.7%

1,274

956

33.3%

35.8%

-2.5%

WW

885

586

51.0%

53.2%

-2.2%

1,679

1,182

42.0%

44.0%

-2.0%

VELCADE

US

-

-

-

-

-

-

-

-

-

-

Intl

379

318

19.2%

22.7%

-3.5%

732

671

9.1%

12.1%

-3.0%

WW

379

318

19.2%

22.7%

-3.5%

732

671

9.1%

12.1%

-3.0%

ZYTIGA

US

174

113

54.0%

54.0%

-

335

213

57.3%

57.3%

-

Intl

221

119

85.7%

85.2%

0.5%

404

219

84.5%

84.4%

0.1%

WW

395

232

70.3%

70.0%

0.3%

739

432

71.1%

71.1%

0.0%

OTHER ONCOLOGY

US

32

6

*

*

-

70

13

*

*

-

Intl

79

30

*

*

-7.4%

138

66

*

*

-6.0%

WW

111

36

*

*

-6.1%

208

79

*

*

-5.0%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

TOTAL OTHER

US

708

609

16.3%

16.3%

-

1,357

1,159

17.1%

17.1%

-

Intl

541

675

-19.9%

-19.9%

0.0%

1,103

1,365

-19.2%

-18.6%

-0.6%

WW

1,249

1,284

-2.7%

-2.7%

0.0%

2,460

2,524

-2.5%

-2.2%

-0.3%

ACIPHEX/PARIET

US

97

104

-6.7%

-6.7%

-

200

200

0.0%

0.0%

-

Intl

59

128

-53.9%

-54.0%

0.1%

108

254

-57.5%

-57.3%

-0.2%

WW

156

232

-32.8%

-32.8%

0.0%

308

454

-32.2%

-32.1%

-0.1%

PROCRIT/EPREX

US

190

232

-18.1%

-18.1%

-

423

436

-3.0%

-3.0%

-

Intl

145

169

-14.2%

-14.6%

0.4%

290

341

-15.0%

-15.3%

0.3%

WW

335

401

-16.5%

-16.7%

0.2%

713

777

-8.2%

-8.3%

0.1%

XARELTO

US

189

49

*

*

-

347

76

*

*

-

Intl

-

-

-

-

-

-

-

-

-

-

WW

189

49

*

*

-

347

76

*

*

-

OTHER

US

232

224

3.6%

3.6%

-

387

447

-13.4%

-13.4%

-

Intl

337

378

-10.8%

-10.5%

-0.3%

705

770

-8.4%

-7.4%

-1.0%

WW

569

602

-5.5%

-5.3%

-0.2%

1,092

1,217

-10.3%

-9.7%

-0.6%

TOTAL PHARMACEUTICAL

US

3,377

3,094

9.1%

9.1%

-

6,848

6,120

11.9%

11.9%

-

Intl

3,648

3,197

14.1%

16.5%

-2.4%

6,945

6,304

10.2%

12.4%

-2.2%

WW

$       7,025

6,291

11.7%

12.9%

-1.2%

$     13,793

12,424

11.0%

12.1%

-1.1%

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2013

2012

Reported

Operational (1)

Currency

2013

2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)

CARDIOVASCULAR CARE

US

$          204

195

4.6%

4.6%

-

$          402

371

8.4%

8.4%

-

Intl

325

309

5.2%

9.6%

-4.4%

640

615

4.1%

8.0%

-3.9%

WW

529

504

5.0%

7.7%

-2.7%

1,042

986

5.7%

8.1%

-2.4%

DIABETES CARE

US

259

337

-23.1%

-23.1%

-

542

689

-21.3%

-21.3%

-

Intl

330

336

-1.8%

-0.5%

-1.3%

647

654

-1.1%

0.2%

-1.3%

WW

589

673

-12.5%

-11.8%

-0.7%

1,189

1,343

-11.5%

-10.9%

-0.6%

DIAGNOSTICS

US

241

258

-6.6%

-6.6%

-

489

511

-4.3%

-4.3%

-

Intl

242

256

-5.5%

-1.5%

-4.0%

471

515

-8.5%

-4.7%

-3.8%

WW

483

514

-6.0%

-4.0%

-2.0%

960

1,026

-6.4%

-4.5%

-1.9%

INFECTION PREVENTION/OTHER

US

95

99

-4.0%

-4.0%

-

180

215

-16.3%

-16.3%

-

Intl

139

131

6.1%

12.3%

-6.2%

266

259

2.7%

8.2%

-5.5%

WW

234

230

1.7%

5.2%

-3.5%

446

474

-5.9%

-2.9%

-3.0%

ORTHOPAEDICS

US 

1,274

873

45.9%

45.9%

-

2,535

1,656

53.1%

53.1%

-

Intl

1,111

755

47.2%

52.4%

-5.2%

2,235

1,465

52.6%

56.3%

-3.7%

WW

2,385

1,628

46.5%

48.9%

-2.4%

4,770

3,121

52.8%

54.5%

-1.7%

SPECIALTY SURGERY

US

331

336

-1.5%

-1.5%

-

650

663

-2.0%

-2.0%

-

Intl

325

310

4.8%

7.5%

-2.7%

633

611

3.6%

6.2%

-2.6%

WW

656

646

1.5%

2.8%

-1.3%

1,283

1,274

0.7%

1.9%

-1.2%

SURGICAL CARE 

US

577

602

-4.2%

-4.2%

-

1,108

1,195

-7.3%

-7.3%

-

Intl

1,011

1,038

-2.6%

0.6%

-3.2%

1,988

2,070

-4.0%

-1.0%

-3.0%

WW

1,588

1,640

-3.2%

-1.2%

-2.0%

3,096

3,265

-5.2%

-3.3%

-1.9%

VISION CARE

US

262

253

3.6%

3.6%

-

543

530

2.5%

2.5%

-

Intl

468

477

-1.9%

6.4%

-8.3%

927

957

-3.1%

4.1%

-7.2%

WW

730

730

0.0%

5.4%

-5.4%

1,470

1,487

-1.1%

3.5%

-4.6%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US

3,243

2,953

9.8%

9.8%

-

6,449

5,830

10.6%

10.6%

-

Intl

3,951

3,612

9.4%

13.7%

-4.3%

7,807

7,146

9.2%

12.9%

-3.7%

WW

$       7,194

6,565

9.6%

12.0%

-2.4%

$     14,256

12,976

9.9%

12.0%

-2.1%

 

* Percentage greater than 100% (1) Operational growth excludes the effect of currency (2) Select areas (unaudited) (3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals (4) Prior year amounts have been reclassified to conform to current year product disclosure (5) Reported as U.S. sales

SOURCE Johnson & Johnson



RELATED LINKS

http://www.jnj.com